Filing Details
- Accession Number:
- 0001104659-25-011677
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-11 21:46:12
- Reporting Period:
- 2025-02-09
- Accepted Time:
- 2025-02-11 21:46:12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1649904 | Rhythm Pharmaceuticals Inc. | RYTM | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1801372 | Kayden Jennifer Lee | C/O Rhythm Pharmaceuticals, Inc. 222 Berkeley Street, 12Th Floor Boston MA 02116 | Evp, Head Of North America | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-02-09 | 3,437 | $0.00 | 4,409 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2025-02-09 | 4,189 | $6.80 | 8,598 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-02-10 | 1,894 | $58.39 | 6,704 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-02-10 | 2,295 | $59.34 | 4,409 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-02-11 | 2,031 | $0.00 | 6,440 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-02-11 | 1,023 | $57.51 | 5,417 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-02-11 | 4 | $57.50 | 5,413 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2025-02-09 | 3,437 | $0.00 | 3,437 | $0.00 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-02-09 | 4,189 | $0.00 | 4,189 | $6.80 |
| Common Stock | Restricted Stock Units | Disposition | 2025-02-11 | 2,031 | $0.00 | 2,031 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 3,437 | No | 4 | M | Direct | ||
| 21,601 | 2032-02-08 | No | 4 | M | Direct | |
| 0 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024.
- The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $58.0750 to $58.8900 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
- The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $59.1400 to $59.3600 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
- The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
- The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date.
- The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
- The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date.
Billionaire Hedge Funds
